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Abstract
Senescence, a hallmark of mammalian aging, is associated with the onset and progression of cardiovascular disease.
Angiotensin II (Ang II) signaling and zinc homeostasis dysfunction are increased with age and are linked to cardiovascular
disease, but the relationship among these processes has not been investigated. We used a model of cellular senescence
induced by Ang II in vascular smooth muscle cells (VSMCs) to explore the role of zinc in vascular dysfunction. We found that
Ang II-induced senescence is a zinc-dependent pathway mediated by the downregulation of the zinc transporters ZnT3 and
ZnT10, which work to reduce cytosolic zinc. Zinc mimics Ang II by increasing reactive oxygen species (ROS), activating
NADPH oxidase activity and Akt, and by downregulating ZnT3 and ZnT10 and inducing senescence. Zinc increases Ang II-
induced senescence, while the zinc chelator TPEN, as well as overexpression of ZnT3 or ZnT10, decreases ROS and prevents
senescence. Using HEK293 cells, we found that ZnT10 localizes in recycling endosomes and transports zinc into vesicles to
prevent zinc toxicity. Zinc and ZnT3/ZnT10 downregulation induces senescence by decreasing the expression of catalase.
Consistently, ZnT3 and ZnT10 downregulation by siRNA increases ROS while downregulation of catalase by siRNA induces
senescence. Zinc, siZnT3 and siZnT10 downregulate catalase by a post-transcriptional mechanism mediated by decreased
phosphorylation of ERK1/2. These data demonstrate that zinc homeostasis dysfunction by decreased expression of ZnT3 or
ZnT10 promotes senescence and that Ang II-induced senescence is a zinc and ROS-dependent process. Our studies suggest
that zinc might also affect other ROS-dependent processes induced by Ang II, such as hypertrophy and migration of smooth
muscle cells.
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Introduction
Aging is associated with physiological changes that increase
predisposition to cardiovascular diseases [1]. For example,
increases in inflammatory responses with age promote atheroscle-
rosis [2], which is thought to result from age-related dysfunction of
the vascular endothelium and smooth muscle cells [3]. Cellular
senescence, a hallmark of mammalian aging, is a process of
permanent cell cycle arrest involving changes in gene expression
and cell morphology [4], such as increase in the expression of
senescence-associated b-galactosidase (SA-b-gal) and increase in
cell size [5]. Senescent vascular cells in culture present similar
changes to the ones observed in aged arteries, such as an increase
in ROS levels in vascular smooth muscle cells (VSMCs) [6].
Senescent VSMCs positive for SA-b-gal have been found in
arteries of old animals [7] and in atherosclerotic plaques [8],
indicating that cellular senescence could contribute to in vivo
vascular aging [9] and atherosclerosis [10]. Thus, the study of
molecular mechanisms regulating cellular senescence in vitro is
important to our understanding of age related pathologies like
atherosclerosis.
Angiotensin II (Ang II) is a potent mediator of vascular disease
including atherosclerosis and the metabolic syndrome [11]. Ang II
signaling pathways become activated with age and contribute to
the development of atherosclerosis [12] as well as vascular
senescence in vivo [13,14] and in vitro in VSMCs [14]. Moreover,
disruption of the Ang II type 1 receptor promotes longevity [15],
suggesting that prevention of Ang II signaling is not only beneficial
to prevent cardiovascular disease but also to delay the aging
process. Ang II induced-senescence involves a p53/p21-dependent
pathway in VSMCs [14]. However, the molecular mechanism is
not fully understood and whether other processes that are also
disrupted by age could modulate this pathway has not been
investigated.
Among the changes induced by age, zinc deficiency is common
in the elderly [16]. Zinc is an important nutritional factor
contributing to the function of the immune system, metabolic
function and antioxidant capacities. Zinc supplementation protects
from oxidative stress in cells in culture [17] and in animal models
[18]. On the other hand, zinc deprivation increases oxidative
stress, induces apoptotic cell death [19] and influences renal and
cardiovascular disease [20]. Importantly, zinc deficiency has been
postulated as a risk factor in the development of atherosclerosis
[21] yet the cellular and molecular basis of this association remains
largely unexplored. Since vascular senescence is increased by age
and Ang II, and zinc homeostasis dysfunction is also increased by
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and Ang II signaling pathways converge to promote vascular
senescence.
Zinc homeostasis is tightly regulated by the expression of
metallothioneins (MTs) and membrane proteins that buffer and
transport zinc, respectively. Zinc transport and distribution are
carried out by two families of zinc transporters [22]. Fourteen
members of the Zips (Zrt/Irt-like proteins)/SLC39 (solute carrier
39) family of zinc importers work to increase cytosolic zinc by
importing zinc from extracellular or from intracellular compart-
ments. In contrast, ten members of the ZnT (zinc transporter)/
SLC30A family of zinc exporters work in the opposite direction to
reduce cytosolic zinc concentration by moving zinc out of the cell
or into various intracellular compartments. Expression of
members of the ZnT family is decreased by age [23] suggesting
that ZnT family members could be relevant in age-related
dysfunction of zinc homeostasis and cardiovascular diseases, but
virtually nothing is known about the expression profile of ZnTs or
about the regulation of zinc homeostasis in the vasculature.
Here we show the expression profile of members of the ZnT
family in VSMCs and mouse aorta and identify ZnT3 and ZnT10
as important regulators of VSMC senescence. We show that Ang
II, as well as zinc, downregulates ZnT3 and ZnT10 expression.
This event decreases catalase expression, which leads to
accumulation in ROS levels and the induction of senescence.
Zinc regulates catalase protein stability by an ERK1/2-dependent
mechanism. Zinc-induced senescence is prevented by the
antioxidant N-acetyl-cysteine (NAC), suggesting that ZnT3 and
ZnT10 work to prevent increases in ROS levels by modulating the
expression of catalase.
Materials and Methods
Antibodies and DNA constructs
The following antibodies were used for western blots: Akt1/2
(H-136) was from Santa Cruz Biotechnology. p21 and P53 were
from GeneTex. Rabbit polyclonal anti-catalase was from Calbio-
chem. Glutathione peroxidase 1 (GPx-1) was from Abcam. SOD1
was from Fisher Scientific. SOD2 was from Stressgen. Monoclonal
antibodies against tubulin and b-actin and rabbit anti-PMP70
were from Sigma. Rabbit polyclonal antibodies against phospho-
Akt (Ser 473), phospho-p38MAPK (Thr 180/Tyr 182) phospho-
p44/42 MAPK (Thr 202/Tyr 204), p38MAPK and p44/42
MAPK were from Cell Signaling. Rabbit antibody against myc
was from Bethyl Laboratories, Inc. Monoclonal antibodies against
Tfr-R (H68.4) were from Invitrogen. Polyclonal antibodies against
green fluorescent protein (GFP) were from Synaptic System
(Go ¨ttingen, Germany). Monoclonal anti-GFP 3E6 and H2-
dichlorofluorescin diacetate (H2DCFDA) were from Molecular
Probes. Ang II and Dulbecco’s modified Eagle’s medium (DMEM)
with 25 mM Hepes and 4.5 g/liter glucose were from Sigma.
Human ZnT10 (NM_018713) myc-tagged plasmid was obtained
from GeneCopoeia
TM (Rockville MD). The human zinc trans-
porters ZnT3-myc, ZnT3-GFP and ZnT4-myc were previously
described [24]. ZnT5-GFP plasmids were obtained from Dr. Juan
M. Falcon-Perez (CIC bioGUNE, Spain) [25]. FoxO1 wt and the
constitutive active mutant FoxO1-CA were obtained from Dr. R.
W. Alexander at Emory University.
Cell culture and transfection
VSMCs from male Sprague-Dawley rat thoracic aortas,
prepared using enzymatic digestion as described [26], were
obtained from Dr. Kathy K. Griendling at Emory University.
Cells were cultured until passage 12 in DMEM (Sigma)
supplemented with 10% bovine serum (Invitrogen), 2 mM
glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin.
HEK293T cells (ATCC Nu CRL-1573) were cultured in DMEM
medium (Cellgro, Herndon, VA; 4.5 g/l glucose) containing 10%
FBS (Hyclone, Lolgan, UT), 100 U/ml penicillin and 100 mg/ml
streptomycin. HEK293 cells transfected with ZnT10-myc plas-
mids were maintained in media containing 0.2 mg/ml G418 as
described previously [27]. For Ang II treatment, cells were growth-
arrested for 24 hrs in DMEM containing 0.5% bovine serum prior
to the addition of 100 nM Ang II or zinc. VSMCs were incubated
with 50 mMH 2O2 (Sigma) for five days and media changed every
24 hrs. The ROS scavenger N-acetyl cysteine (NAC, Sigma,
1 mM), the Akt inhibitor V Tribicirine (TCN) and ERK1/2
inhibitor PD98059 were added to cells 30 min prior to the
addition of 50 mM ZnSO4 and maintained during the zinc
incubation.
For Transfection experiments, VSMCs at 70–90% confluency
were transfected using the basic NucleofectorH (Lonza Walkers-
ville, Inc.)) kit for primary smooth muscle cells (Lonza, p13
program). Cells were allowed to recover for 48 hrs before further
treatments. HEK293 cells were transfected using 4 mlo f
Lipofectamine 2000 for 16 hrs. After 48 hrs, transfected cells
were selected with 0.8 mg/ml G418 for one week. Colonies were
isolated with cloning rings and expression of target proteins tested
by immunofluorescence.
Reverse transcription PCR (RT-PCR) and RNA interference
RNA was isolated from VSMCs grown in 60 mm petri dishes
and from mouse aorta using the RNeasy kit (Qiagen), according to
manufacturer’s instructions. The SuperScript
TM One Stept RT-
PCR system (Invitrogen) was used with 0.5 mg of total RNA to
amplify target genes. Primers used to determine the expression of
SLC30A/ZnTs zinc transporters are described in Table S1.
GAPDH control primers were designed to recognize both rat and
mouse targets. Downregulation by siRNA of target genes was
performed using the basic NucleofectorH kit for primary smooth
muscle cells. Oligonucleotides used for siRNA are described in
Table S2. Downregulation efficiency was determined by RT-PCR
or by western blot as appropriate.
Zinpyr-1 staining and immunofluorescence
Cells cultured in MatTek dishes (Mat Tek Corp) were treated
with and without ZnSO4, TPEN or Ang II in DMEM, washed
and incubated with 10 mM Zinpyr-1 (Ex/Em=515/525) in DPBS
for 30 min at 37uC. Cells were then washed in DPBS and imaged
with a confocal microscope (Zeiss LSM 510 META) using the
488 nm argon laser line and filter set HQ480/406;HQ535/50m
(Chroma). Images were acquired using a Plan Apochromat 636
oil immersion objective NA=1.4. Fluorescence intensity was
determined using MetaMorph software 3.0 (Molecular Devices,
Sunnyvale, CA).
Immunofluorescence was performed as described previously
[28]. Briefly, cells grown on coverslips were fixed with 4%
paraformaldehyde (PFA), washed with PBS and permeabilized in
blocking buffer containing 0.02% saponin. Alexa FluorH 488 and
Alexa FluorH 568 were used as secondary antibodies. Samples
were examined using the 488- and 543-nm lines of the argon ion
and green HeNe lasers with 515/30-nm band pass and 585-nm-
long pass filters, respectively, in a confocal imaging system (Zeiss
LSM 510 META).
ROS measurements
VSMCs seeded in 24-well plates were growth-arrested for
24 hrs in DMEM and treated with or without 100 nM Ang II,
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were incubated with 10 mM2 9,79-dichlorodihydrofluorescein
diacetate (H2DCFDA) for 30 min, washed twice and fluorescence
intensity determined using a CytoFluor multi-well plate reader
(Applied Biosystems (ABI) PerSeptive Biosystems).
NADPH oxidase activity
NADPH oxidase activity was measured in membrane fractions
using lucigenin as described [29]. Briefly, VSMCs were incubated
with or without 50 mM zinc for 4 hrs, washed and lysed in 20 mM
KH2PO4 buffer, pH 7.4. Samples were sonicated and centrifuged
for 15 min at 28,0006g. Pellets containing total membranes were
resuspended in 50 mM KH2PO4 assay buffer and incubated with
0.1 mM lucigenin and 1 mM NADPH. NADPH oxidase activity
was determined by subtracting the luminescence before and after
the addition of the superoxide scavenger Tiron (100 mM).
Senescence associated b-galactosidase staining
SA-b-gal activity was determined as described [5]. Cells plated
at low density in 12-well plates were growth-arrested in DMEM
containing 0.5% bovine serum for 24 hrs and incubated with Ang
II, zinc, TPEN or H2O2 in the same media for 3 to 10 days. Cells
were then washed twice with PBS, fixed with 0.2% glutaraldehyde
in PBS for 10 min and incubated in 40 mM phosphate buffer
containing 1 mg/ml X-Gal, 150 mM NaCl, 2 mM MgCl2,5m M
K3Fe(CN)6 and 5 mM K4Fe(CN)6 overnight at 37uC. Cells were
washed twice with PBS and kept in 70% glycerol. Images were
acquired using an Olympus IX71 microscope using a 106
objective. SA-b-gal positive cells were counted in 10 different
fields/well (3 to 6 individual wells per condition) and expressed as
a percentage of total cell number. Detection of SA-b-gal with the
Galacto-Light Plus
TM System (Applied Biosystems) was performed
according to manufacturer’s instructions. After treatment, samples
were lysed and luminescence determined after 20 min incubation
using a TD-20/20 luminometer (Turner Designs, Sunnyvale CA).
Western blots
VSMCs were lysed in lysis buffer (50 mM Hepes, pH 7.4,
50 mM NaCl, 1% Triton X-100, 5 mM EDTA, 10 mM sodium
pyrophosphate, 50 mM sodium fluoride, and 1 mM sodium
orthovanadate) plus anti-protease cocktail (Sigma) and total
homogenates separated on 4–20% PAGE-SDS Criterion pre-cast
gels (Bio Rad). Protein expression was determined by enhanced
chemiluminescence using specific antibodies.
Cell viability
Cells grown to 80% confluency in 24-well plates were incubated
with ZnSO4 or TPEN in DMEM containing 0.5% bovine serum
for one to ten days. Cell viability was determined by trypan-blue
exclusion using a Neubauer chamber. 100% viability was
determined in the absence of zinc or TPEN.
Statistics
All data are depicted as average 6 standard deviation of the
mean. Statistical significance was determined by Student’s t test
and accepted at p,0.05(*). ** denotes p,0.01.
Results
Zinc increases ROS and induces senescence of VSMCs
To investigate if zinc homeostasis regulatory mechanisms and
Ang II signaling pathways interact to promote vascular senes-
cence, we first determined whether addition of exogenous zinc
could increase intracellular zinc levels and enhance Ang II
signaling in VSMCs. We incubated VSMCs with zinc and
monitored the level of intracellular zinc using the specific zinc
fluoroprobe Zinpyr-1 [30] (Fig. 1A). VSMCs show a basal
vesicular and perinuclear staining that was increased by zinc
and was reduced by the zinc chelator TPEN (Fig. 1A and Fig.
S1A). We next tested if increases in intracellular zinc levels could
affect Ang II signaling by monitoring Akt, p38MAPK and ERK1/
2 phosphorylation (Fig. 1B). These three kinases mediate Ang II
effects in VSMCs [31]. Pre-incubation with zinc increases Akt and
p38MAPK and decreases ERK1/2 phosphorylation in basal
conditions (Fig. 1B, lane 7) and after Ang II treatment (Fig. 1B,
compare lanes 2–6 and 8–12). Since Akt and p38MAPK, but not
ERK1/2, are activated by Ang II in a ROS-dependent manner in
VSMCs [31] and senescence is induced by ROS [32], we tested
whether zinc could increase ROS levels and induce senescence.
Zinc increased ROS levels 1.460.28, 1.9760.28 and 2.1260.4-
fold after incubations with 25, 50 and 100 mM zinc, respectively
(n=7, p,0.01) (Fig. 1C). Increases in ROS levels by 50 mM zinc
(1.9960.4-fold n=8, p,0.01 vs control) were similar to the ones
observed after Ang II treatment (1.9460.28-fold n=4, p,0.01 vs
control) (Fig. 1D). Furthermore, zinc increased NADPH oxidase
activity 1.8260.18-fold (n=3, p,0.01) (Fig. 1E).
To determine senescence, we incubated VSMCs with increasing
concentrations of zinc for five days and measured SA-b-gal
activity, a senescence marker. 50 mM zinc is the optimal
concentration for long-term incubations based on cell viability
assays (Fig. S1B) and ROS production (Fig. 1C). Senescence was
increased from 10.861.1% to 1860.34%, 24.463.36% and
34.3362.42% after treatment with 12.5, 25 and 50 mM zinc,
respectively (Fig. 1F). Similar to Ang II, zinc increased SA-b-gal
staining over time (Fig. 1G and 1H). Zinc also increased the
expression of the senescence markers p21 and p53 (Fig. 1I) as
previously reported for Ang II in VSMCs [14]. Thus, zinc mimics
Ang II by activating NADPH oxidase activity, increasing ROS
levels, activating the ROS sensitive p38MAPK/Akt pathway and
inducing senescence.
Zinc is required for Ang II-induced senescence
The fact that zinc mimics Ang II effects led us to hypothesize
that zinc could be required for Ang II-induced senescence. This
hypothesis predicts that Ang II-induced increases in ROS levels
and senescence should be increased by zinc and prevented by
TPEN (Fig. 2). ROS levels induced by Ang II were significantly
increased by zinc (1.4360.04-fold vs 1.360.06-fold, n=6,
p,0.01) and were reduced by TPEN (0.96860.24-fold, n=6,
p,0.01). Further, basal as well as zinc-induced increases in ROS
were also reduced by TPEN (Fig. 2A). Next, we incubated VSMCs
with Ang II in the presence of zinc or TPEN for three days to
determine senescence. Cell viability assays show that 100 nM
TPEN is a non-toxic concentration for long-term incubations (Fig.
S1C). This concentration is 100 times lower than the concentra-
tion (10 mM TPEN) described to remove zinc from zinc containing
proteins such as transcriptional factors [33]. Zinc increases and
TPEN reduces Ang II-induced senescence (Fig. 2B–D). Ang II
treatment leads to 27.962.8% SA-b-gal positive cells compared to
6.162.4% in control cells (p,0.01). The effect of Ang II was
increased to 34.961.6% (p,0.05 vs Ang II) when cells were co-
incubated with 50 mM zinc, and was reduced to 11.361.65%
(p,0.01 vs Ang II) when cells were co-incubated with 100 nM
TPEN (Fig. 2C). Similar results were observed when SA-b-gal
activity was determined by quantitative chemiluminescence using
the Galacto-Light Plus
TM System (Applied Biosystems) (Fig. 2D).
We detected an increase of 1.3560.14-fold (n=6, p,0.01) in Ang
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Incubation with 50 and 100 mM zinc increased Ang II-induced
senescence 1.7560.05-fold (n=6, p,0.01) and 2.3460.57-fold
(n=3, p,0.05), respectively, compared to Ang II alone. In
contrast, TPEN prevents Ang II effects (0.8860.03-folds, n=3,
p=0.24 vs control). Thus, zinc increases ROS levels and
senescence while TPEN prevents them. To further evaluate the
dependence of ROS in zinc-induced senescence, we incubated
VSMCs with zinc in the presence or absence of the antioxidant
NAC (Fig. 2E and F). The increase in senescence induced by zinc
(50.664.4%) was similar to incubation with H2O2 alone
(66.9610.44%, p,0.05 vs zinc). NAC significantly reduced zinc-
induced senescence to 2561.2% (p,0.01 vs zinc). All together,
these data indicate that zinc is required for Ang II-induced
senescence via a ROS-dependent mechanism.
Ang II downregulates zinc transporters ZnT3 and ZnT10
to induce senescence
The observation that zinc is required for Ang II-induced
senescence suggests that Ang II may affect the availability and/or
distribution of free zinc and, therefore, zinc homeostasis to
mediate senescence. To test this idea, we monitored changes in
intracellular zinc using Zinpyr-1 staining in VSMCs treated for
three days with Ang II alone or together with TPEN (Fig. 3A). Ang
II induced changes in zinc distribution from a vesicular to a
perinuclear Golgi-like staining in 64.3% of cells (14 different fields)
Figure 1. Zinc increases ROS levels, activates the ROS-dependent Ang II signaling pathway and induces senescence in VSMC. A)
VSMCs incubated with 25, 50 or 100 mM zinc in the presence or absence of 25 mM TPEN for 1 hr were incubated with Zinpyr-1 and imaged by
confocal microscopy (Bar=20 mm). B) Cells pre-incubated with 100 mM zinc for 1 hr were incubated with 100 nM Ang II for 5 to 30 min, lysed and
analyzed by immunoblot with the indicated antibodies. Cells treated with 25, 50 or 100 mM zinc (C) or with 50 mM zinc or 100 nM Ang II for 30 min
(D) were incubated with H2DCFDA to determine ROS levels. E) NADPH oxidase activity was determined by lucigenin assay after 4 hrs with 50 mM zinc.
F) SA-b-gal activity was determined after treatment with and without 12.5, 25 or 50 mM zinc for five days. G and H) Cells were treated with and
without 100 nM Ang II or 50 mM zinc for three, five or ten days and senescence determined by counting SA-b-gal positive cells (Bar=200 mm). I)
Expression of p21 and p53 was determined after five days incubation with 50 mM zinc. * and ** denote p,0.05 and p,0.01, respectively. ns=non-
significant differences.
doi:10.1371/journal.pone.0033211.g001
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was reduced by TPEN. The change in zinc distribution suggests
that Ang II may affect the expression of SLC30A/ZnT family
members of zinc transporters, which work to reduce cytosolic zinc
concentration by moving zinc out of the cells or inside vesicular
compartments, such as endosomes and Golgi. We determined
mRNA expression levels of SLC30A/ZnT family members by
RT-PCR and found that VSMCs, as well as mouse aorta, express
eight out of ten members of the ZnT family (Fig. 3B). We found
ZnT1, that localizes at the plasma membrane [34], ZnT3 and
ZnT4 that localize at endosomes [27,35], and ZnT5, ZnT6 and
ZnT7 found at the Golgi complex [36]. We also found ZnT9/
HUEL, which was shown to translocate to the nucleus in a cell-
cycle dependent manner [37], and ZnT10, whose subcellular
localization and zinc transporter capacities have not been
investigated. Next, we determined ZnTs mRNA expression levels
in response to Ang II treatment. Ang II downregulated the
expression of ZnT3 and ZnT10, but not other ZnTs (Fig. 3C and
3J).
To determine the functional consequences of ZnT3 and
ZnT10 downregulation by Ang II, we knocked down their
expression levels by siRNA (Fig. S2A and S2B) and determined
senescence by SA-b-gal staining (Fig. 3F and 3G). ZnT3 and
ZnT10 downregulation decreased the levels of vesicular zinc
(Fig. 3D and 3E) and increased basal senescence to 24.7263.6%
and 25.9762.65%, respectively. These levels are similar to those
observed in cells treated with Ang II in control conditions
(23.4165.19%). Similar to Ang II and zinc treatments,
downregulation of both ZnTs also increased the expression of
the senescence marker p21 and p53 (Fig. 3H). Further, ZnT3 and
ZnT10 downregulation increased Ang II-induced senescence
(Fig. 3G). These data suggest that downregulation of ZnT3 and
ZnT10 might lead to increases of zinc in the cytosol before the
addition of Ang II, which could accelerate senescence (more SA-
b-gal positive cells). This idea is supported by the fact that zinc
alone increases, while TPEN prevents, senescence. This hypoth-
esis predicts that increases of cytosolic zinc by downregulation of
any other zinc transporter should also induce senescence. To test
this idea, we knocked down the Ang II-insensitive ZnT5 by
siRNA (Fig. S2C) and found that this treatment also induces
senescence (Fig. 3F and 3G). siZnT5 increased basal (15.48%6
3.05%, p,0.01 vs control cells) as well as Ang II-induced
senescence (36.8867.9%, p,0.01, vs Ang II in control cells),
suggesting that zinc homeostasis dysfunction mediates senescence
of VSMCs. Further, no changes in cellular distribution of Ang II-
insensitive ZnTs, such as ZnT5 and ZnT4 was observed by Ang
II (Fig. S3).
Since expression of zinc transporters such as ZnT1 are
transcriptionally regulated by zinc [38] and zinc induces
senescence (Fig. 1F–I), we asked whether ZnT3 and ZnT10 could
be downregulated by zinc. Both ZnTs mRNA were downregulated
by zinc similar to Ang II (Fig. 3I and 3J), suggesting that increase
in zinc levels could be mediated by Ang II in an early event
upstream of ZnTs downregulation. All together, these data show
that Ang II downregulates the zinc transporters ZnT3 and ZnT10
to induce senescence.
Figure 2. Zinc is required for Ang II-induced senescence by a ROS-dependent pathway. A) Cells incubated with and without Ang II in the
presence or absence of 50 mM zinc or 100 nM TPEN for 30 min were incubated with H2DCFDA to determine ROS levels. SA-b-gal activity was
determined after three (B–D) or five (E and F) days by counting SA-b-gal positive cells (C and F) or by quantitative luminescence (D). E and F) Cells
were incubated with zinc, zinc plus 1 mM NAC or 50 mMH 2O2 and senescence determined by SA-b-gal staining. Bar=200 mm.
doi:10.1371/journal.pone.0033211.g002
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induced senescence
To further test the role of ZnT3 and ZnT10 in Ang II-induced
senescence, we asked whether overexpression of these transporters
could prevent Ang II effects. Western blots with anti-myc
antibodies confirmed ZnT10 and ZnT3 overexpression and show
that VSMCs express lower levels of these transporters compared
with HEK293 cells after transfection (Fig. 4A). A discrete
overexpression of ZnT3 or ZnT10 decreased ROS levels
0.3761.6 and 0.6260.14-fold, respectively (Fig. 4B) and prevent-
ed Ang II-induced senescence (Fig. 4C and D). VSMCs
overexpressing ZnT10-myc were 23.361.35% positive for SA-b-
gal compared to 41.664%, p,0.05 in mock-transfected cells
treated with Ang II. Non-significant (ns) differences were observed
between transfected and mock-transfected cells in basal conditions
or between transfected cells with and without Ang II (23.361.4
and 2164%, respectively, p=0.4). Similarly, ZnT3 overexpres-
sion reduced Ang II-induced senescence from 49.2363.08% in
mock-transfected cells to 23.9161.68% (p,0.01). Thus, overex-
pression of ZnT3 and ZnT10 mimics the effects of TPEN by
decreasing ROS levels and preventing senescence, suggesting that
senescence is mediated by zinc. Thus, these data show that Ang II-
induced senescence is a zinc-dependent process mediated by the
downregulation of ZnT3 and ZnT10.
Figure 3. Ang II downregulates the zinc transporters ZnT3 and ZnT10 to induce senescence. A) VSMCs incubated with 100 nM Ang II for
three days in the presence or absence of 100 nM TPEN were incubated with Zinpyr-1 and imaged by confocal microscopy. B) Total mRNA was used to
determine ZnT1 to ZnT10 expression levels by RT-PCR in VSMCs and mouse aorta using GAPDH as control. All primers were designed to recognize
mouse and rat ZnTs, except for ZnT1 and ZnT3 (see Table S1). C) mRNA prepared from VSMCs treated for one to three days with 100 nM Ang II was
used to determine expression of the indicated ZnTs by RT-PCR. Cells treated with siRNA to downregulate ZnT3 and ZnT10 were imaged with Zinpyr-1
(D and E) or processed for SA-b-gal staining (F and G) or western blot to determine p21 and p53 expression (H). siZnT5-treated cells were analyzed for
SA-b-gal staining (F and G). I and J) Cells were treated with Ang II, zinc or both for three days and samples analyzed by RT-PCR and quantified respect
to GAPDH control. Bar=10 mm in A and D and 200 mm in F. * and ** represent p,0.05 and p,0.01, respectively.
doi:10.1371/journal.pone.0033211.g003
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capacity
We hypothesize that overexpression of ZnT3 or ZnT10 should
prevent increases in cytosolic zinc to prevent senescence.
However, ZnT10 zinc transport capacities have not been
explored. The transport capacity of ZnT3 is well-documented
[24,27]. To investigate the mechanism by which ZnT10
downregulation induces senescence, we first determined ZnT10
subcellular localization and zinc transport capacities. We analyzed
ZnT10 subcellular localization in HEK293 cells transfected with
the human ZnT10 myc tagged (Fig. 5A). We choose HEK293 cells
because they are easily transfected (Fig. 4A) and suitable for
morphological studies. In this cell line, ZnT10 strongly colocalizes
with markers of recycling endosomes, such as the transferrin
receptor (Tfr-R) (69.39611.21%, n=14 cells) and rab11 (data not
shown) and with the early endosome marker EEA1
(16.2164.38%, n=13 cells), but not with syntaxin 8 (data not
shown) or CD63 (1.8360.93%, n=10 cells), markers of late
endosome and lysosomes, respectively. Moreover, ZnT10 co-
localizes (63.7612%, n=12 cell, Fig. 5B) and interacts (Fig. 5C)
with ZnT3 which also resides in Tfr-R-positive endosomes [27].
Immunoprecipitation with anti-GFP antibodies brings down
ZnT10-myc in cells co-expressing ZnT10-myc and ZnT3-GFP
in the presence or absence of the cross-linker DSP (Fig. 5C, lanes 6
and 7). We previously used DSP to detect labile interactions and to
demonstrate the formation of ZnT3 dimers [24]. ZnT10 and
ZnT3 form stable dimers (D) and oligomers (O) that may mediate
zinc accumulation/transport into recycling endosomes.
We next determined ZnT10 zinc transport capacities in colonies
of HEK293 cells permanently transfected with ZnT10-myc (Fig.
S4, colony Nu 18, 100% expression), using Zinpyr-1 to visualize
vesicular zinc accumulation (Fig. 5D and 5E). Fluorescence
intensity (zinc accumulation) was higher in ZnT10-transfected
compared with mock-transfected cells in both basal (751.43656.4
vs 190.46623.12, n=39 cells) and zinc-treated conditions
(1,121661 vs 650654.7, n=37 cells). Zinpyr-1 fluorescence
staining resembles the vesicular and perinuclear ZnT10-positive
signal detected with anti myc antibodies by immunofluorescence
(Fig. S4). To further assess ZnT10 transport capacities, we
determined whether ZnT10 overexpression could confer resis-
tance to zinc toxicity (Fig. 5F). Cells overexpressing ZnT10-myc
showed a significant increase in cell viability (71615%, n=6,
p,0.01) compared with mock-transfected cells (27.564.6%) after
a challenge with toxic levels of zinc. Thus, ZnT10 functions to
transport zinc into early/recycling endosomes.
Zinc and ZnT3/ZnT10 downregulation decrease catalase
expression to induce senescence
We next explored the mechanism by which zinc and ZnT3/
ZnT10 downregulation promotes senescence. We focused on
catalase because transient activation of the ROS-dependent Akt,
but not the ERK1/2 pathway, mediates catalase downregulation
by Ang II in VSMCs [39]. We show that zinc increases ROS levels
(Fig. 1C and 1D) and activates Akt, but not ERK1/2 (Fig. 1B).
Zinc reduced catalase protein expression (Fig. 6A and Fig. S5A),
similar to Ang II alone (Fig. 6A, 4764.94%, n=5, p,0.01 vs
Figure 4. Overexpression of ZnT3 and ZnT10 decreases ROS and prevents Ang II-induced senescence. A) ZnT3 and ZnT10 expression
was determined by immunoblot with anti-myc antibodies in control and transfected VSMCs and HEK293 cells, using b-actin and transferrin receptor
(Tfr-R) as loading controls. B) ROS levels were measured with H2DCFDA in mock or ZnT3 and ZnT10 transfected VSMCs cells. C and D) Senescence was
determined by counting SA-b-gal positive cells in control and ZnT3-myc and ZnT10-myc transfected cells treated with 100 nM Ang II for five days.
Bar=200 mm in C. ** represents p,0.01.
doi:10.1371/journal.pone.0033211.g004
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levels of catalase and prevents its downregulation by Ang II
(Fig. 6A and Fig. S5A). These data support the idea that TPEN
prevents Ang II-induced senescence by preventing increases in
ROS levels (Fig. 2A) and catalase downregulation. Time course
experiments show that catalase, but not the peroxisomal
membrane protein PMP70, was significantly downregulated after
two days of zinc incubation (Fig. 6B and 6C), indicating that
peroxisome biogenesis was not affected. No significant changes
were observed in other antioxidant enzymes, such as SOD1,
SOD2 or glutathione peroxidase-1 (GPx-1) after three days of
zinc incubation (Fig. 6B and 6C). Akt and ERK1/2 phosphor-
ylation was increased and decreased by zinc, respectively (Fig. 6B).
Since zinc also downregulates ZnT3 and ZnT10, we asked
whether downregulation of zinc transporters is upstream of
catalase reduction. Knock down of ZnT3 and ZnT10 by siRNA
decreased catalase (Fig. 6D and 6E) and increased ROS levels
2.1160.43-fold and 2.0760.33-fold (n=12, p,0.01) compared
to siControl-treated cells (0.9860.14), respectively (Fig. 6F).
Downregulation of catalase increased ROS levels 3.7561.51-fold
(n=9, p,0.01).
To determine the role of catalase in the senescence mechanism
induced by zinc and ZnT3/ZnT10 downregulation, we knocked
down catalase by siRNA and determined senescence (Fig. 6G).
p21 expression (Fig. S5B) as well as SA-b-gal staining was
increased by siCatalase (45.8164.79%) compared to siControl
cells (16.6462.03%, p,0.01). Ang II (38.3662.46%) and zinc-
induced (36.2461.9%) senescence was increased to 58.462.39%
and 51.8164.65%, respectively by catalase siRNA (Fig. 6G).
Consistently, overexpression of catalase (Fig. S5C) significantly
Figure 5. ZnT10 localizes and transports zinc into early/recycling endosomes in HEK293 cells. HEK293 cells transfected with ZnT10-myc
alone (A) or together with ZnT3-GFP (B) were fixed in 4% PFA and analyzed by immunofluorescence with monoclonal antibodies against Tfr-R, EEA1
and CD63 (A) and polyclonal antibodies against myc (A and B). Images were acquired with a confocal microscope using a 636/oil objective. C)
HEK293 cells transiently transfected with ZnT10-myc and ZnT3-GFP were cross-linked with 1 mM DSP, lysed and Triton X-100 soluble extracts
immunoprecipitated with monoclonal antibodies against myc. ZnT3 and ZnT10 interaction (lanes 6 and 7) was determined by western blots using
polyclonal antibodies against myc and GFP. 10 mg of Triton X-100 soluble extracts were used as inputs (lanes 8–10). D and E) Control and HEK293
stable cells lines expressing ZnT10-myc were incubated with and without zinc and stained with Zinpyr-1. Fluorescence intensity was determined by
confocal microscopy and quantified using MetaMorph software. F) Cell viability was determined by trypan-blue exclusion in HEK293 control and
ZnT10-myc expressing cells after incubations with 100 mM zinc for 24 hrs. Bar=10 mm in A, B and D.
doi:10.1371/journal.pone.0033211.g005
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senescence to 11.863.8% and 1565.1%, respectively (Fig. 6H).
Zinc downregulates catalase by a post-transcriptional
ERK1/2-dependent mechanism
Ang II downregulates catalase by an Akt/FoxO1-dependent
and ERK1/2-independent transcriptional mechanism [39]. Zinc
increases Akt phosphorylation, suggesting that zinc may act by a
similar mechanism. In fact, NAC that prevented zinc-induced
senescence (Fig. 2F) also prevented Akt phosphorylation and
catalase downregulation by zinc (Fig. 7A and 7C). However,
inhibition of Akt with the inhibitor V tricibirine (TCN) increased
basal levels of catalase similar to NAC, but failed to prevent
catalase downregulation by zinc (Fig. 7A, lanes 5 and 6 and 7C).
No changes in Akt expression were observed by NAC or TCN. To
further test the role of the Akt/FoxO1 pathway on zinc effects, we
overexpressed FoxO1 wild type and the constitutive active mutant
FoxO1-CA (T24A/S319A) that is not phosphorylated and
inactivated by Akt [40]. Overexpression of FoxO1 constructs
increased basal levels of catalase (Fig. 7B, lanes 3 and 5). Zinc
downregulated catalase expression similarly in control conditions
and after FoxO1 wt and CA overexpression (Fig. 7B and 7C),
suggesting that zinc might regulate catalase by a post-transcrip-
tional mechanism. Consistent with this idea, catalase mRNA levels
were not affected by zinc (Fig. S6A and B).
We next tested whether inhibition of ERK1/2 by zinc could
mediate zinc effects. Similar to zinc, the ERK1/2 inhibitor
PD98059 (PD) decreased catalase and increased p21 expression
(Fig. 7D and 7E) and SA-b-gal staining (Fig. 7F and 7G). ZnT3
and ZnT10 siRNA also decreased ERK1/2 phosphorylation
(Fig. 7H and 7I) while ZnT3 and ZnT10 overexpression increased
ERK1/2 phosphorylation and catalase expression (Fig. 7J and
7K). Thus, zinc and ZnT3/ZnT10 regulate catalase expression by
an Akt-independent ERK1/2-dependent post-transcriptional
mechanism.
All together, these data demonstrate that zinc and downregu-
lation of ZnT3 and ZnT10 decrease catalase expression leading to
increases of ROS levels senescence of VSMCs.
Discussion
Our findings, summarized in Fig. 8, demonstrate that Ang II-
induced senescence requires a zinc-dependent pathway mediated
by the downregulation of the zinc transporters ZnT3 and ZnT10.
This event would disrupt zinc homeostasis leading to downregu-
lation of catalase and increases in ROS levels that promotes
senescence. Zinc shows similar effects to Ang II. Zinc increases
ROS levels, activates NADPH oxidase activity (Fig. 1C–E),
decreases ZnT3, ZnT10 (Figs. 3I an J) and catalase expression
(Fig. 6A–C) and increases senescence (Fig. 1G–I). In contrast, the
Figure 6. Downregulation of catalase by zinc, Ang II, siZnT3 and siZnT10 mediates senescence in VSMCs. A) Cells incubated with and
without 100 nM Ang II, zinc (25 or 50 mM) or 100 nM TPEN for five days were lysed and catalase expression determined by western blots. B and C)
VSMCs incubated with and without 50 mM zinc for one, two or three days were lysed and protein expression of the indicated antioxidant enzymes
determined by western blots and quantified after 3 days (C). D and E) Catalase expression was determined by western blot after ZnT3 and ZnT10
knock down by siRNA. F) Cells treated with siRNA to downregulate ZnT3, ZnT10 or catalase (Cat) were incubated with H2DCFDA to determine ROS
levels. SA-b-gal positive cells were counted in siControl and siCatalase-treated cells (G) and in catalase-transfected cells (H) after five days treatment
with and without Ang II or zinc 50 mM. ** and ns denote p,0.01 and non-statistic differences, respectively.
doi:10.1371/journal.pone.0033211.g006
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decrease ROS levels (Fig. 2A and 4B), increase catalase expression
(Figs. 6A, 7J and 7K) and prevent Ang II-induced senescence
(Figs. 2B–D, 4C and 4D). Consistently, downregulation of ZnT3,
ZnT10 or catalase by siRNA increases ROS (Fig. 6F) and
senescence (Figs. 3F, 3G and 6G). Further, zinc-induced
downregulation of catalase and senescence is prevented by NAC
(Figs. 7A, 2E and 2F). To our knowledge, this is the first evidence
linking Ang II signaling and zinc homeostasis regulatory
mechanisms, such as zinc transporters, in a senescence pathway.
The observations that zinc increases ROS levels and
activates Akt, similar to Ang II, lead us to speculate that zinc
levels could increase after Ang II stimulation. Increases in zinc
levels could be caused by release of zinc from zinc containing
proteins and/or from membrane compartments. In VSMCs, we
identified eight out of the ten members of the SLC30A/ZnT
family of zinc transporters, which are responsible for zinc
accumulation in membrane compartments. ZnT3, ZnT4 and
ZnT10 localize in endosomes and ZnT5, ZnT6 and ZnT7 in
the Golgi complex. Thus, endosomes and/or Golgi could serve
as reservoirs of free zinc for signal transduction in VSMCs.
Alternatively, zinc could be ejected from zinc-binding proteins,
such as MTs. MT is a family of cysteine-rich metal-binding
proteins that bind labile zinc, which could be released by
cysteine oxidation [41]. Zinc is redox inert but it binds to
proteins through sulfurs of cysteines, allowing its rapid
exchange by the redox environment. An interesting possibility
is that Ang II-induced increases of ROS levels could lead to
zinc release from proteins/compartments leading to increases
in free zinc. This free zinc could further activate NADPH
oxidase activity and increase ROS leading to the induction of
senescence. The source of zinc that activates Ang II signaling
and increases ROS remains to be elucidated.
Our data are in agreement with the reported effects of zinc in
signaling pathways in other cellular systems. In HepG2 human
hepatoma cells, zinc activates the PI3K/Akt pathway, inducing
the phosphorylation, inactivation and nuclear exclusion of FoxO1
[42]. Zinc shows insulin-mimetic effects by activating the insulin-
dependent signaling cascade [43]. The effects of zinc in the insulin
pathway are ROS-dependent. In rat adipocytes, zinc increases the
generation of H2O2 and superoxide to stimulate glucose
metabolism [44]. Moreover, zinc activates NADPH oxidase
activity and increases ROS in cortical neurons [45,46] and in
the renal epithelial cell line, LLC-PK1 [47]. Here we show that
zinc also activates a NADPH oxidase in VSMCs (Fig. 1E). Aortic
VSMCs express Nox1 and Nox4 [48], which has been associated
with cellular senescence [49]. The nature of the zinc-induced
Nox(es) remains to be elucidated.
Figure 7. Catalase is downregulated by zinc by an Akt-independent ERK1/2-dependent post-transcriptional pathway. VSMCs treated
with and without 1 mM NAC, 1 mM of the Akt inhibitor V tricibirine (TCN) (A and C) or transfected with FoxO1 wt or FoxO1-CA (B and C) were
incubated with or without 50 mM zinc for three days and protein expression determined by western blots with the indicated antibodies. C) The effect
of zinc was quantified for each condition independently, considering basal levels of catalase with or without NAC, TCN or FoxO1 overexpression as 1.
Cells incubated for three days with 50 mM zinc or 2 mM of the ERK1/2 inhibitor PD98059 (PD) were processed for western blot to determine catalase
expression (D and E) or for SA-b-gal staining (F and G). Bar=100 mm in F. VSMCs treated with siZnT3 and siZnT10 (H and I) or transfected with ZnT3-
myc or ZnT10-myc plasmids (J and K) were lysed and protein levels of p-ERK1/2 (I and K) and catalase (K) quantified by western blots. ** and ns
denote p,0.01 and non-statistic differences, respectively.
doi:10.1371/journal.pone.0033211.g007
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mechanisms. Ang II downregulates catalase by an Akt-dependent
(ERK1/2-independent) acetylation/inactivation of the transcrip-
tional coactivator PGC-1a (peroxisome proliferator-activated
receptor gamma co-activator-1a), leading to reduced binding of
FoxO1 to the catalase promoter [39]. Akt and its upstream kinase
p38MAPK, but not ERK1/2, are activated by Ang II in a ROS-
dependent manner in VSMCs [31]. Although zinc activates Akt
phosphorylation, Akt inhibition, as well as overexpression of
FoxO1 wt or a constitutive active mutant (FoxO1-CA), failed to
prevent zinc-induced downregulation of catalase. Instead, zinc
decreases catalase by decreasing ERK1/2 phosphorylation
without affecting catalase mRNA levels (Fig. S6A and B).
Inhibition of ERK1/2 phosphorylation with PD98059 decreases
catalase expression and induces senescence (Fig. 7D–G). siZnT3/
ZnT10 and ZnT3/ZnT10 overexpression decreases and increases
ERK1/2 phosphorylation and catalase, respectively (Fig. 7H–K),
suggesting that ZnT3/ZnT10 are upstream of ERK1/2. These
data are in agreement with recent observations that ZnT3
regulates presynaptic ERK1/2 signaling, which is required for
hippocampus-dependent memory [50]. The data presented here
have important implications in the possible role of ZnT3
regulating ROS levels in the brain. Future studies will determine
whether regulation of ROS levels by ZnT3/ZnT10 is also
observed in other tissues.
The differential mechanism of catalase downregulation by Ang
II and zinc may explain why zinc and siZnT3/siZnT10 show
additive effects on Ang II-induced senescence. At least two
pathways are involved in catalase downregulation. One involves a
transcriptional mechanism mediated by Ang II-dependent activa-
tion of a ROS/Akt/FoxO1 pathway [39]. The anti-oxidant NAC,
which inhibits Akt phosphorylation as well as the Akt inhibitor
TCN, increase basal levels of catalase (Fig. 7A). Consistently,
overexpression of FoxO1 wt and the Akt-insensitive mutant
FoxO1-CA also increase catalase expression (Fig. 7B), suggesting
that catalase is in fact regulated by a ROS/Akt/FoxO1
transcriptional mechanism. The second is a zinc-dependent post-
transcriptional mechanism involving ROS/ZnT3/ZnT10/
ERK1/2 that regulates catalase protein stability. Ang II also
downregulates ZnT3 and ZnT10, but activates ERK1/2 signaling.
Addition of zinc to Ang II-treated cells will decrease ERK1/2
signaling leading to a decrease in catalase mRNA levels and
protein stability, which will further increase senescence. Zinc may
affect catalase protein stability by preventing synthesis and/or
increasing degradation. For example, zinc was shown to increase
the ubiquitination of the phosphatase PTEN leading to its
proteasome-dependent degradation with the subsequent activation
of the PI3K/Akt pathway [51]. Catalase is also regulated by
ubiquitination and proteosome degradation in mouse embryo
fibroblasts and HEK293 cells [52].
Here, we reported the subcellular localization and zinc
transport capacities of the zinc transporter ZnT10. ZnT10
localizes in rab11 and Tfr-R positive recycling endosomes,
similarly to the localization of ZnT3 in PC12 cells [27]. Using
Zinpyr-1 staining and zinc toxicity assays, we show that ZnT10
indeed transports zinc likely into early/recycling endosomes. We
hypothesize that downregulation of ZnT3 or ZnT10 would disrupt
zinc homeostasis by increasing its concentration in the cytosol.
This hypothesis predicts that downregulation of any other ZnT
would induce similar phenotypes. In fact, we found that ZnT5
siRNA, a zinc transporter localized in the Golgi complex [36] and
that is insensitive to downregulation by Ang II, induces basal
senescence. siZnT5 also increases Ang II-induced senescence to
similar levels compared with siZnT3 and siZnT10 (Fig. 3F and G).
These data suggest that ZnT3, ZnT10 and ZnT5 regulate zinc
homeostasis to prevent increases of zinc in the cytosol and to
prevent senescence.
In conclusion, we demonstrated that Ang II-induced senescence
is a zinc-dependent process regulated by the downregulation of
ZnT3 and ZnT10 leading to the decreased expression of catalase.
Zinc mimics Ang II by increasing ROS levels, activating NADPH
oxidase activity and Akt, decreasing ZnT3 and ZnT10, reducing
catalase and inducing senescence. Our studies suggest that zinc
may also affect other Ang II-induced and/or ROS-dependent
processes, such as hypertrophy and migration of smooth muscle
cells. These findings inform a cellular and molecular mechanism to
understand the putative role of zinc homeostasis dysfunction in the
development of atherosclerosis. We propose that manipulation of
metal pools may modify the outcome of cardiovascular diseases.
Future experiments will determine if zinc homeostasis dysfunction,
such as zinc deficiencies in vivo, may exacerbate Ang II
maladaptive effects. This information will provide important
insight into possible nutritional interventions to lessen Ang II-
induced age-dependent diseases.
Supporting Information
Figure S1 Intracellular zinc measurements and cell
viability in response to long-term incubations with zinc
or TPEN. VSMCs were incubated with and without zinc (25 to
100 mM) or TPEN (100 or 250 nM) for 1 hr (A) or for one to ten
days (B and C). A) Quantification of Zinpyr-1 fluorescence
intensity shown in Fig. 1A was determined using MetaMorph
software and expressed as mean 6 SE. B and C) Cell viability was
determined by trypan-blue exclusion. **: p,0.01, ns=non-
significant differences.
(TIF)
Figure S2 Expression of ZnT3, ZnT5 and ZnT10 de-
crease after siRNA treatment. Cells were incubated with
Figure 8. Model representing Ang II and zinc-dependent
senescence mechanisms. Similar to Ang II, zinc activates NADPH
oxidase activity, increases ROS levels and Akt phosphorylation and
downregulates ZnT3, ZnT10 and catalase. However, Ang II-induced
downregulation of catalase is mediated by an Akt-dependent
transcriptional mechanism, while zinc-induced downregulation of
catalase is mediated by an ERK1/2-dependent post-transcriptional
mechanism. Downregulation of catalase further increases ROS that
mediates senescence. Perpendicular red arrows indicate increased or
reduced expression.
doi:10.1371/journal.pone.0033211.g008
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Samples were separated in agarore gels and images inverted using
Photoshop software. Relative mRNA levels were calculated with
respect to GAPDH expression. **: p,0.01.
(TIF)
Figure S3 Subcellular localization of ZnT4 and ZnT5 is
not affected by Ang II in VSMCs. Cells transfected with
ZnT4-myc or ZnT5-GFP plasmids were incubated with or
without Ang II for three days. Cells were fixed and incubated
with anti-myc or anti-GFP antibodies. Images were acquired using
a confocal microscope. Bar=10 mm.
(TIF)
Figure S4 Expression of ZnT10-myc in transfected
HEK293 cells. Permanently transfected HEK293 cells (colony
Nu18) were fixed with 4% PFA and incubated with polyclonal
anti-myc antibodies. Alexa FluorH 568 was used as a secondary
antibody. Samples were imaged using a confocal microscope.
Bar=10 mm.
(TIF)
Figure S5 Catalase expression is downregulated by zinc
and siCatalase. VSMCs were incubated with 50 mM zinc or
100 nM TPEN for five days (A), siCatalase (B) or transfected with
plasmids containing catalase (C). Data on A represent quantifica-
tion of catalase expression shown in Fig. 6A, expressed as percent
versus control. **: p,0.01.
(TIF)
Figure S6 Zinc downregulates catalase by a post-
transcriptional mechanism. A) Catalase mRNA levels were
determined by RT-PCR after treatment with or without 50 mM
zinc for three days. B) Catalase relative mRNA was calculated
respect to GAPDH expression.
(TIF)
Table S1 Primers used to determine mRNA levels of
mouse (m) and rat (r) ZnTs by RT-PCR. Primers were
design to recognize mouse and rat ZnTs, except for ZnT1 and
ZnT3.
(TIF)
Table S2 Oligonucleotide sequence for siRNA downreg-
ulation.
(TIF)
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